A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
A phase 1 trial of Mavorixafor and Ibrutinib in Waldenström macroglobulinaemia, run by X4 Pharmaceuticals, completed.
Overview
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 is a phase 1 interventional study registered as NCT04274738 by X4 Pharmaceuticals, with 16 participants recorded, started 2020-04-30 and reaching its primary completion in 2022-10-31. Interventions recorded: Mavorixafor, Ibrutinib. Conditions recorded: Waldenstrom's Macroglobulinemia.
Linked to the drug Mavorixafor because the registry names it among its interventions and Waldenström macroglobulinaemia among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialX4P-001 and Pembrolizumab in Patients With Advanced Melanoma
Shares X4 Pharmaceuticals, Mavorixafor and the tag pipeline.
- TrialAn Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Shares Waldenström macroglobulinaemia and the tag pipeline.
- TrialDose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Shares Waldenström macroglobulinaemia and the tag pipeline.
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Ibrutinib and the tag pipeline.
- TrialStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Shares Ibrutinib and the tag pipeline.
- TrialStudy of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Shares Ibrutinib and the tag pipeline.
- TrialA Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Shares Waldenström macroglobulinaemia and the tag pipeline.
- TrialA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Shares Ibrutinib and the tag pipeline.